Chimeric protein in the treatment of amyloidosis
AssigneesCentre National de la Recherche Scientifique (CNRS), Universitéde Limoges
InventorsChristophe De Romeuf, Christophe Sirac, Jean-Claude Brouet
Life of this patent
Estimating the term…
Abstract
The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.
Claims21
A method for treating in an individual with systemic amyloidosis comprising administering an effective amount of a chimeric protein to the individual, wherein the chimeric protein comprises from N-terminal part to C-terminal part
- (i) a human serum amyloid P compound (SAP);
- (ii) a first hinge region;
- (iii) a first Fc region of a human antibody;
- (iv) a spacer chain;
- (v) a second hinge region;
- and
- (vi) a second Fc region of a human antibody;
- wherein the chimeric protein is a single polypeptide chain comprising a functional dimeric Fc region.
Dependencies are inferred from the claim text.